Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex
US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in the development of protein therapeutics, which are used in various commercial and development-stage biopharma drug candidates. As per the terms of the deal, Ligand Pharmaceuticals is offering to acquire the […]